S&P 500 7,459.94 â–ŧ 73.83 (-0.98%) DOW 52,169.10 â–ŧ 383.87 (-0.73%) NASDAQ 25,535.42 â–ŧ 346.53 (-1.34%) US Markets Closed â€ĸ 09:08 AM ET

ALLR

Allarity Therapeutics, Inc.

Price Chart
Latest Quote

$1.17

-0.01 (-0.85%)
Current Price
Previous Close $1.18
Open $1.18
Day High $1.20
Day Low $1.12
Volume 92,468
Fetched: 2026-07-17T05:18:45
Stock Information
Shares Outstanding 15.91M
Total Debt $21.50M
Cash Equivalents $19.81M
Revenue $345K
Net Income $-11.25M
Sector Healthcare
Industry Biotechnology
Market Cap $18.93M
EPS (TTM) $-0.70
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$20.62M
Sales$345K
Income$-11.25M
Book/sh$0.44
Cash/sh$1.25
Employees7
Financial Ratios
Quick Ratio0.75
Current Ratio1.23
Debt/Eq310.64
Returns & Margins
ROA-23.70%
ROE-87.92%
Gross Margin100.00%
Operating Margin-10752.00%
Ownership
Insider Ownership4.19%
Institutional Ownership5.97%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-1.23
P/S54.88
P/B2.72
Analyst Data
Recommendationnone
Target Price$10.25
Technical Indicators
SMA20$1.24
SMA50$1.44
SMA200$1.26
RSI38.30
ATR0.0919
Shares Float15.61M
Short Float0.51%
Short Ratio0.48
Volatility0.53
Rel Volume0.61
Performance History
Week+2.15%
Month-16.78%
Quarter-4.03%
6 Months-1.65%
YTD+4.39%
Year+19.00%
3 Years-99.94%
10 Years-100.00%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-07-17 $1.19 82,900
2026-07-16 $1.17 102,600
2026-07-15 $1.18 81,200
2026-07-14 $1.16 100,000
2026-07-13 $1.13 69,800
2026-07-10 $1.16 103,200
2026-07-09 $1.20 55,700
2026-07-08 $1.16 163,600
2026-07-07 $1.13 430,000
2026-07-06 $1.20 151,000
2026-07-02 $1.31 116,500
2026-07-01 $1.33 132,800
2026-06-30 $1.29 166,800
2026-06-29 $1.30 71,600
2026-06-26 $1.30 121,300
2026-06-25 $1.27 147,600
2026-06-24 $1.30 68,700
2026-06-23 $1.32 80,000
2026-06-22 $1.36 153,200
2026-06-18 $1.43 297,900
About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $320,000 $0 $0 $0
Operating Revenue $320,000 $0 $0 $0
Expenses
Interest Expense $185,000 $653,000 $498,000 $223,000
Total Expenses $12,925,000 $17,538,000 $17,129,000 $16,892,000
Other Income Expense $758,000 $-7,238,000 $5,787,000 $-494,000
Net Non Operating Interest Income Expense $616,000 $-120,000 $-476,000 $-193,000
Interest Expense Non Operating $185,000 $653,000 $498,000 $223,000
Operating Expense $12,925,000 $17,538,000 $17,129,000 $16,892,000
General And Administrative Expense $6,324,000 $11,442,000 $10,026,000 $9,962,000
Other Non Operating Income Expenses - - $-591,000 -
Total Other Finance Cost - - - -
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-11,231,000 $-24,515,000 $-11,901,000 $-16,058,000
Net Interest Income $616,000 $-120,000 $-476,000 $-193,000
Interest Income $801,000 $533,000 $22,000 $30,000
Normalized Income $-11,989,000 $-17,387,768 $-16,939,620 $-15,606,743
Net Income From Continuing And Discontinued Operation $-11,231,000 $-24,515,000 $-11,901,000 $-16,058,000
Total Operating Income As Reported $-12,605,000 $-27,241,000 $-17,129,000 $-34,463,000
Net Income Common Stockholders $-11,231,000 $-25,154,000 $-20,416,000 $-21,051,000
Net Income $-11,231,000 $-24,515,000 $-11,901,000 $-16,058,000
Net Income Including Noncontrolling Interests $-11,231,000 $-24,515,000 $-11,901,000 $-16,058,000
Net Income Continuous Operations $-11,231,000 $-24,515,000 $-11,901,000 $-16,058,000
Pretax Income $-11,231,000 $-24,896,000 $-11,818,000 $-17,579,000
Special Income Charges $0 $-9,703,000 $0 $-16,591,000
Interest Income Non Operating $801,000 $533,000 $22,000 $30,000
Operating Income $-12,605,000 $-17,538,000 $-17,129,000 $-16,892,000
Per Share
Diluted EPS $-0.78 $-15.65 $-6031.31 $-31799.09
Basic EPS $-0.78 $-15.65 $-6031.31 $-31799.09
Other
Tax Effect Of Unusual Items $0 $-110,768 $1,339,380 $-42,743
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-11,804,000 $-16,996,000 $-17,661,000 $-16,802,000
Total Unusual Items $758,000 $-7,238,000 $6,378,000 $-494,000
Total Unusual Items Excluding Goodwill $758,000 $-7,238,000 $6,378,000 $-494,000
Reconciled Depreciation $-13,000 $9,000 $37,000 $60,000
EBITDA (Bullshit earnings) $-11,046,000 $-24,234,000 $-11,283,000 $-17,296,000
EBIT $-11,046,000 $-24,243,000 $-11,320,000 $-17,356,000
Diluted Average Shares $14,378,942 $1,606,989 $3,385 $662
Basic Average Shares $14,378,942 $1,606,989 $3,385 $662
Diluted NI Availto Com Stockholders $-11,231,000 $-25,154,000 $-20,416,000 $-21,051,000
Tax Provision $0 $-381,000 $83,000 $-1,521,000
Impairment Of Capital Assets $0 $9,703,000 $0 $17,571,000
Gain On Sale Of Security $758,000 $2,465,000 $6,378,000 $16,097,000
Research And Development $6,601,000 $6,096,000 $7,103,000 $6,930,000
Selling General And Administration $6,324,000 $11,442,000 $10,026,000 $9,962,000
Other Gand A $6,324,000 $11,442,000 $10,026,000 $9,962,000
Preferred Stock Dividends - $639,000 $8,515,000 $4,993,000
Gain On Sale Of Ppe - - $0 $1,780,000
Other Special Charges - - - $800,000
Minority Interests - - - -
Fetched: 2026-07-06
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $9,828,000 $11,811,000 $-12,622,000 $-7,659,000
Total Assets $18,258,000 $22,650,000 $11,862,000 $14,544,000
Total Non Current Assets $330,000 $309,000 $9,891,000 $9,576,000
Current Assets $17,928,000 $22,341,000 $1,971,000 $4,968,000
Prepaid Assets $2,346,000 $579,000 $859,000 $727,000
Receivables $895,000 $2,229,000 $946,000 $871,000
Taxes Receivable $895,000 $813,000 $946,000 $871,000
Accounts Receivable $0 $1,416,000 $0 -
Cash Cash Equivalents And Short Term Investments $14,687,000 $19,533,000 $166,000 $2,029,000
Cash And Cash Equivalents $14,687,000 $19,533,000 $166,000 $2,029,000
Cash Financial $14,687,000 $19,533,000 $166,000 $2,029,000
Goodwill And Other Intangible Assets - $0 $9,871,000 $9,549,000
Other Intangible Assets - - $9,871,000 $9,549,000
Current Deferred Assets - - $0 $1,341,000
Investmentin Financial Assets - - - -
Debt
Total Debt $1,400,000 $1,350,000 $1,300,000 $3,735,000
Current Debt And Capital Lease Obligation $1,400,000 $1,350,000 $1,300,000 $2,652,000
Current Debt $1,400,000 $1,350,000 $1,300,000 $2,644,000
Other Current Borrowings $1,400,000 $1,350,000 $1,300,000 $2,644,000
Net Debt - - $1,134,000 $1,698,000
Long Term Debt And Capital Lease Obligation - - - $1,083,000
Long Term Debt - - - $1,083,000
Liabilities
Total Liabilities Net Minority Interest $8,430,000 $10,839,000 $14,613,000 $12,654,000
Total Non Current Liabilities Net Minority Interest $0 $0 $446,000 $1,432,000
Current Liabilities $8,430,000 $10,839,000 $14,167,000 $11,222,000
Payables And Accrued Expenses $7,030,000 $9,488,000 $9,784,000 $8,196,000
Interest Payable $461,000 $281,000 $101,000 $0
Payables $4,363,000 $4,256,000 $8,475,000 $6,292,000
Total Tax Payable $81,000 $74,000 $59,000 $41,000
Income Tax Payable $81,000 $74,000 $59,000 $41,000
Accounts Payable $4,282,000 $4,182,000 $8,416,000 $6,251,000
Non Current Deferred Liabilities - $0 $446,000 $349,000
Non Current Deferred Taxes Liabilities - $0 $446,000 $349,000
Other Current Liabilities - $1,000 $3,083,000 $374,000
Current Notes Payable - - $0 $2,644,000
Derivative Product Liabilities - - - -
Equity
Common Stock Equity $9,828,000 $11,811,000 $-4,493,000 $-113,000
Total Equity Gross Minority Interest $9,828,000 $11,811,000 $-2,751,000 $1,890,000
Stockholders Equity $9,828,000 $11,811,000 $-2,751,000 $1,890,000
Gains Losses Not Affecting Retained Earnings $-1,021,000 $-354,000 $-411,000 $-721,000
Other Equity Adjustments $-1,021,000 $-354,000 $-411,000 $-721,000
Retained Earnings $-130,197,000 $-118,966,000 $-94,451,000 $-82,550,000
Preferred Stock Equity - - $1,742,000 $2,003,000
Preferred Securities Outside Stock Equity - - $0 $0
Other
Treasury Shares Number $2,949,639 - $0 -
Ordinary Shares Number $16,080,980 $7,302,797 $9,811 $662
Share Issued $19,030,619 $7,302,797 $9,811 $662
Tangible Book Value $9,828,000 $11,811,000 $-14,364,000 $-9,662,000
Invested Capital $11,228,000 $13,161,000 $-3,193,000 $3,614,000
Working Capital $9,498,000 $11,502,000 $-12,196,000 $-6,254,000
Total Capitalization $9,828,000 $11,811,000 $-2,751,000 $2,973,000
Treasury Stock $3,190,000 $0 - -
Additional Paid In Capital $144,233,000 $131,130,000 $90,369,000 $83,158,000
Capital Stock $3,000 $1,000 $1,742,000 $2,003,000
Common Stock $3,000 $1,000 $0 $0
Current Accrued Expenses $2,667,000 $5,232,000 $1,309,000 $1,904,000
Net PPE $330,000 $309,000 $20,000 $27,000
Gross PPE $330,000 $309,000 $20,000 $27,000
Other Properties $330,000 $309,000 $20,000 $27,000
Preferred Stock - $0 $1,742,000 $2,003,000
Capital Lease Obligations - - $0 $8,000
Current Capital Lease Obligation - - $0 $8,000
Long Term Capital Lease Obligation - - - $0
Other Short Term Investments - - - $0
Line Of Credit - - - -
Investments And Advances - - - -
Available For Sale Securities - - - -
Accumulated Depreciation - - - -
Fetched: 2026-07-06
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-14,828,000 $-17,650,000 $-12,745,000 $-16,835,000
Operating Activities
Operating Cash Flow $-14,820,000 $-17,352,000 $-12,745,000 $-16,817,000
Cash Flow From Continuing Operating Activities $-14,820,000 $-17,352,000 $-12,745,000 $-16,817,000
Operating Gains Losses $1,237,000 $-2,803,000 $-5,833,000 $-18,340,000
Investing Activities
Capital Expenditure $-8,000 $-298,000 - $-18,000
Investing Cash Flow $-8,000 $-298,000 $0 $791,000
Cash Flow From Continuing Investing Activities $-8,000 $-298,000 $0 $791,000
Financing Activities
Repurchase Of Capital Stock $-3,190,000 $-3,500,000 $-6,654,000 $-1,511,000
Issuance Of Capital Stock $13,838,000 $40,292,000 $18,055,000 $0
Financing Cash Flow $10,648,000 $36,792,000 $10,995,000 $-1,311,000
Cash Flow From Continuing Financing Activities $10,648,000 $36,792,000 $10,995,000 $-1,311,000
Net Preferred Stock Issuance $0 $-562,000 $-5,494,000 $-1,511,000
Preferred Stock Issuance $0 $2,938,000 $1,160,000 $0
Net Common Stock Issuance $10,648,000 $37,354,000 $16,895,000 $0
Common Stock Issuance $13,838,000 $37,354,000 $16,895,000 $0
Net Other Financing Charges - - - $-800,000
Other
Repayment Of Debt $0 $-1,340,000 $-3,699,000 $0
Issuance Of Debt $0 $1,340,000 $1,050,000 $1,000,000
End Cash Position $14,687,000 $19,533,000 $166,000 $2,029,000
Beginning Cash Position $19,533,000 $166,000 $2,029,000 $19,555,000
Effect Of Exchange Rate Changes $-667,000 $225,000 $-113,000 $-189,000
Changes In Cash $-4,179,000 $19,142,000 $-1,750,000 $-17,337,000
Preferred Stock Payments $0 $-3,500,000 $-6,654,000 $-1,511,000
Common Stock Payments $-3,190,000 $0 - -
Net Issuance Payments Of Debt $0 $0 $-2,649,000 $1,000,000
Net Long Term Debt Issuance $0 $0 $-2,649,000 $1,000,000
Long Term Debt Payments $0 $-1,340,000 $-3,699,000 $0
Long Term Debt Issuance $0 $1,340,000 $1,050,000 $1,000,000
Net PPE Purchase And Sale $-8,000 $-298,000 $0 $-18,000
Purchase Of PPE $-8,000 $-298,000 $0 $-18,000
Change In Working Capital $-5,680,000 $63,000 $3,352,000 $-328,000
Change In Other Current Assets $-150,000 $94,000 $1,350,000 $-1,077,000
Change In Payables And Accrued Expense $-3,831,000 $-557,000 $2,226,000 $1,466,000
Change In Accrued Expense $-2,699,000 $3,536,000 $43,000 $-4,722,000
Change In Payable $-1,132,000 $-4,093,000 $2,183,000 $6,188,000
Change In Account Payable $-1,139,000 $-4,108,000 $2,165,000 $6,207,000
Change In Tax Payable $7,000 $15,000 $18,000 $-19,000
Change In Income Tax Payable $7,000 $15,000 $18,000 $-19,000
Change In Prepaid Assets $-1,603,000 $274,000 $-190,000 $-618,000
Change In Receivables $-96,000 $45,000 $-26,000 $0
Other Non Cash Items $385,000 $566,000 $1,574,000 $138,000
Stock Based Compensation $482,000 $71,000 $-71,000 $1,752,000
Asset Impairment Charge $0 $9,703,000 $0 $17,571,000
Deferred Tax $0 $-446,000 $97,000 $-1,612,000
Deferred Income Tax $0 $-446,000 $97,000 $-1,612,000
Depreciation Amortization Depletion $-13,000 $9,000 $37,000 $60,000
Depreciation And Amortization $-13,000 $9,000 $37,000 $60,000
Gain Loss On Investment Securities $-1,000 $-2,677,000 $-5,654,000 $-17,010,000
Net Foreign Currency Exchange Gain Loss $1,238,000 $-126,000 $-179,000 $450,000
Net Income From Continuing Operations $-11,231,000 $-24,515,000 $-11,901,000 $-16,058,000
Proceeds From Stock Option Exercised - $0 $2,243,000 $0
Change In Other Working Capital - $207,000 - -
Change In Other Current Liabilities - $0 $-8,000 $-99,000
Interest Paid Supplemental Data - - $34,000 $85,000
Income Tax Paid Supplemental Data - - $6,000 $12,000
Net Intangibles Purchase And Sale - - $0 $809,000
Sale Of Intangibles - - $0 $809,000
Gain Loss On Sale Of PPE - - $0 $-1,780,000
Net Short Term Debt Issuance - - - $0
Changes In Account Receivables - - - -
Fetched: 2026-07-06